← 產業報告目錄

Residual DNA Testing Market by Product & Service (Consumable, Instrument & Software), Technology (PCR), Test Type (Raw, Final, Bulk Lot Release Testing), Application (mAb, CGT, Vaccine), End User (Pharma & Biotech, CRO & CDMO) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-07-01頁數 357報告編號 BT9405

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The residual DNA testing market is projected to reach USD 0.37 billion by 2030 from USD 0.28 billion in 2025, at a CAGR of 6.0% during the forecast period. The expansion of this market is fueled by multiple factors, including the increasing frequency of approvals for biologics and biosimilars, as well as the implementation of rigorous regulatory frameworks governing the manufacture of biopharmaceutical products. Additionally, advancements in technologies related to residual DNA testing are anticipated to further bolster market growth throughout the forecast period. By technology, the PCR segment accounted for the largest share of the residual DNA testing market in 2024. By technology, the market is segmented into PCR, threshold Assays, DNA probe hybridization, and other technologies. In 2024, the Polymerase Chain Reaction (PCR) segment commanded the largest share of the market, reflecting its pivotal role in molecular diagnostics. This substantial market share can be primarily attributed to the high sensitivity and specificity offered by PCR, which enables the precise detection of even minute quantities of residual DNA. As a result, PCR effectively minimizes the risk of false positives, a critical factor in ensuring accurate test outcomes. Moreover, the versatility of the PCR technology plays a significant role in its widespread adoption. It can be easily adapted for various test types, making it applicable across a broad spectrum of biopharmaceutical applications. This adaptability, combined with its scalability, allows PCR to be employed in everything from small-scale research studies to large-scale clinical testing, catering to the evolving needs of the biopharmaceutical industry. With its exceptional performance characteristics and flexible applications, the PCR segment continues to be a cornerstone of advancements in molecular biology and diagnostics. In 2024, by end user, the pharmaceutical & biotechnology companies segment accounted for the largest share of the residual DNA testing services market. The residual DNA testing services market is categorized into two primary segments: pharmaceutical & biotechnology companies and academic & research institutes. As of 2024, the pharmaceutical & biotechnology companies segment holds the largest share of the market. This substantial growth can be attributed to the increasing emphasis on the development of biologics, which are innovative therapies aimed at treating a variety of diseases, including cancers, autoimmune disorders, and genetic conditions. As the industry evolves, pharmaceutical and biotechnology firms are required to adhere to stringent regulatory standards, which mandate the provision of comprehensive data concerning the entire manufacturing process. This includes the rigorous testing and validation of biological products to ensure their safety and efficacy. Consequently, the necessity for thorough quality inspections and regulatory approvals becomes paramount, driving the demand for residual DNA testing services. These services play a critical role in identifying and quantifying residual DNA left in biologics, ensuring that products meet safety guidelines and are free from contaminants that could pose risks to patients. Moreover, as companies invest in advanced biotechnological research and development, the demand for reliable and accurate testing methods continues to rise. This trend further augments the market for residual DNA testing services, highlighting its essential role in the pharmaceutical landscape. As the sector strives for innovation and compliance, the importance of these testing services will likely increase, underscoring their value in advancing medical science and patient safety. In 2024, North America accounted for the largest share of the residual DNA testing market. In 2024, North America emerged as the dominant force in the market, largely due to the strong presence of key industry leaders and a notable expansion in research initiatives aimed at innovating and developing biologics. This growth can be attributed to a significant increase in research and development investments within the life sciences sector, which, in turn, has escalated the demand for residual DNA testing products and services. Additionally, the region benefits from a concentration of numerous global entities, including pharmaceutical companies, biotech firms, and academic institutions, which collectively enhance its leadership position in the market. This collaborative environment fosters innovation and accelerates advancements in biologics, further solidifying North America's role as a pivotal hub for life sciences R&D. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40% • By Designation: CXOs and Directors- 30%, Managers- 45%, and Executives- 25% • By Region: North America -35%, Europe - 25%, Asia Pacific -15%, Latin America -10%, Middle East- 10%, and Africa- 5% List of companies profiled in the report: • Thermo Fisher Scientific Inc. (US) • Merck KGaA (Germany) • Eurofins Scientific (Luxembourg) • Charles River Laboratories (US) • Bio-Rad Laboratories (US) • QIAGEN (Germany) • F. Hoffmann-La Roche Ltd (Switerland) • Maravai LifeSciences (US) • FUJIFILM Corporation (Japan) • SGS Société Générale de Surveillance SA (Switzerland) • Jiangsu Hillgene Biopharma Co.,Ltd (China) • Revvity (US) • Intertek Group plc (UK) • WuXi AppTec (China) • Sartorius AG (Germany) • Lonza (Switzerland) Research Coverage: This research report categorizes residual DNA testing market by offering (products and services), technology (PCR, threshold assay, DNA probe hybridization, and other technologies), test type (final product release testing, bulk lot release testing, and final product release testing), application (monoclonal antibodies, cell & gene therapy, vaccines, and other applications), end user for products (pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes), end user for services (pharmaceutical & biotechnology companies and academic & research institutes), and region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa). The report offers an in-depth examination of the critical elements shaping the residual DNA testing market, including key drivers, constraints, challenges, and emerging opportunities. It presents a comprehensive analysis of leading industry players, detailing their business models, product and service offerings, strategic initiatives, new launches, acquisitions, and recent advancements pertinent to the residual DNA testing sector. Additionally, this report includes a competitive landscape assessment of emerging startups within the residual DNA testing ecosystem. Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the residual DNA testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities. The report provides insights on the following: • Analysis of key drivers (Increase in biologics and biosimilars approvals, stringent regulatory compliance requirements, technological advancements in DNA quantification and detection, increasing cell culture contamination risks, rising investments in R&D spending), restraints (high cost of advanced testing techniques, lack of standardization across testing protocols), opportunities (application in novel modalities such as mRNA vaccines, cell therapies, and gene therapies, growth opportunities in emerging markets, integration with continuous and accelerated bioprocessing, rising outsourcing to CROs and CDMOs), and challenges (complexity in sample preparation and assay validation) are influencing the growth of the residual DNA testing market. • Product Development/Innovation: Detailed insights on newly launched products of the residual DNA testing market. • Market Development: Comprehensive information about lucrative markets – the report analyses the residual DNA testing market across varied regions. • Market Diversification: Exhaustive information about new products and services, recent developments, and investments in the residual DNA testing market. • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), and Eurofins Scientific (Luxembourg), among others, offering products and services for the residual DNA testing market. Other companies in this market include TransGen Biotech Co., Ltd. (China), Vazyme International LLC (China), and EagleBio (US).
目錄 Table of Contents
1 INTRODUCTION 36 1.1 STUDY OBJECTIVES 36 1.2 MARKET DEFINITION 36 1.3 STUDY SCOPE 37 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 37 1.3.2 INCLUSIONS & EXCLUSIONS 38 1.3.3 YEARS CONSIDERED 39 1.3.4 CURRENCY CONSIDERED 39 1.4 STAKEHOLDERS 39 2 RESEARCH METHODOLOGY 40 2.1 RESEARCH DATA 40 2.1.1 SECONDARY DATA 41 2.1.1.1 Key sources of secondary data 41 2.1.1.2 Key objectives of secondary research 41 2.1.2 PRIMARY DATA 42 2.1.2.1 Breakdown of primaries 42 2.1.2.2 Key objectives of primary research 42 2.2 MARKET ESTIMATION METHODOLOGY 43 2.2.1 MARKET ESTIMATION 43 2.2.1.1 Company revenue analysis (bottom-up approach) 43 2.2.1.2 Insights of primary experts 45 2.2.2 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH) 46 2.3 MARKET GROWTH RATE PROJECTIONS 47 2.4 DATA TRIANGULATION 49 2.5 STUDY ASSUMPTIONS 50 2.6 RESEARCH LIMITATIONS 51 2.7 RISK ANALYSIS 51 3 EXECUTIVE SUMMARY 52 4 PREMIUM INSIGHTS 57 4.1 RESIDUAL DNA TESTING MARKET OVERVIEW 57 4.2 NORTH AMERICA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE AND COUNTRY 58 4.3 RESIDUAL DNA TESTING PRODUCTS MARKET SHARE, BY END USER, 2024 58 4.4 RESIDUAL DNA TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59   5 MARKET OVERVIEW 60 5.1 INTRODUCTION 60 5.2 MARKET DYNAMICS 60 5.2.1 DRIVERS 61 5.2.1.1 Increasing number of biologics and biosimilar approvals 61 5.2.1.2 Stringent regulatory compliance requirements 62 5.2.1.3 Technological advancements in DNA quantification and detection 63 5.2.1.4 Increasing risk of cell culture contamination 63 5.2.1.5 Rising biopharmaceutical R&D investments 64 5.2.2 RESTRAINTS 64 5.2.2.1 High costs of advanced testing techniques 64 5.2.2.2 Lack of standardization across testing protocols 65 5.2.3 OPPORTUNITIES 65 5.2.3.1 Rising number of applications in novel modalities 65 5.2.3.2 High growth opportunities in emerging markets 67 5.2.3.3 Integration with continuous and accelerated bioprocessing 67 5.2.3.4 Rising outsourcing to CROs and CDMOs 68 5.2.4 CHALLENGES 68 5.2.4.1 Complexity in sample preparation and assay validation 68 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 69 5.4 PRICING ANALYSIS 69 5.4.1 AVERAGE SELLING PRICE TREND OF RESIDUAL DNA TESTING PRODUCTS, BY KEY PLAYER, 2022–2024 70 5.4.2 AVERAGE SELLING PRICE TREND OF RESIDUAL DNA TESTING PRODUCTS, BY REGION, 2022–2024 71 5.5 VALUE CHAIN ANALYSIS 73 5.6 ECOSYSTEM ANALYSIS 74 5.6.1 ROLE IN ECOSYSTEM 76 5.7 INVESTMENT & FUNDING SCENARIO 77 5.8 TECHNOLOGY ANALYSIS 78 5.8.1 KEY TECHNOLOGIES 78 5.8.1.1 Quantitative PCR (qPCR) 78 5.8.1.2 Droplet digital PCR (ddPCR) 78 5.8.1.3 Next-generation sequencing (NGS) 79 5.8.2 COMPLEMENTARY TECHNOLOGIES 79 5.8.2.1 Automated magnetic bead-based DNA extraction 79 5.8.2.2 Capillary electrophoresis 79 5.8.2.3 Nanopore sequencing 79 5.8.3 ADJACENT TECHNOLOGIES 80 5.8.3.1 High-performance liquid chromatography (HPLC) 80 5.8.3.2 Electron microscopy 80 5.8.3.3 Mass spectrometry 80 5.9 PATENT ANALYSIS 81 5.9.1 LIST OF KEY PATENTS 82 5.10 KEY CONFERENCES & EVENTS, 2025–2026 83 5.11 REGULATORY ANALYSIS 83 5.11.1 REGULATORY FRAMEWORK 83 5.11.1.1 North America 84 5.11.1.1.1 US 84 5.11.1.1.2 Canada 84 5.11.1.2 Europe 84 5.11.1.2.1 UK 85 5.11.1.3 Asia Pacific 85 5.11.1.3.1 China 85 5.11.1.3.2 Japan 85 5.11.1.3.3 India 85 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86 5.12 PORTER’S FIVE FORCES ANALYSIS 87 5.12.1 BARGAINING POWER OF SUPPLIERS 89 5.12.2 BARGAINING POWER OF BUYERS 89 5.12.3 THREAT OF NEW ENTRANTS 89 5.12.4 THREAT OF SUBSTITUTES 89 5.12.5 INTENSITY OF COMPETITIVE RIVALRY 90 5.13 KEY STAKEHOLDERS & BUYING CRITERIA 90 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 90 5.13.2 KEY BUYING CRITERIA, BY END USER 91 5.14 IMPACT OF AI/GEN AI ON RESIDUAL DNA TESTING MARKET 92 5.14.1 MARKET POTENTIAL OF AI IN RESIDUAL DNA TESTING 92 5.14.2 AI USE CASES 93 5.14.3 KEY COMPANIES IMPLEMENTING AI/GEN AI 93 5.14.4 FUTURE OF AI/GEN AI IN RESIDUAL DNA TESTING MARKET 93 5.15 TRADE DATA ANALYSIS 94 5.15.1 IMPORT DATA FOR HS CODE 9027, 2020–2024 94 5.15.2 EXPORT DATA FOR HS CODE 9027, 2020–2024 95 5.16 IMPACT OF 2025 US TARIFF ON RESIDUAL DNA TESTING MARKET 95 5.16.1 KEY TARIFF RATES 96 5.16.2 PRICE IMPACT ANALYSIS 97 5.16.3 IMPACT ON COUNTRIES/REGIONS 98 5.16.3.1 North America 98 5.16.3.1.1 US 98 5.16.3.2 Europe 98 5.16.3.3 Asia Pacific 98 5.16.3.4 Rest of the World 98 5.16.4 IMPACT ON END-USE INDUSTRIES 99 5.16.4.1 Pharmaceutical & biotechnology companies 99 5.16.4.2 CROs & CDMOs 99 5.16.4.3 Academic & research institutes 99 6 RESIDUAL DNA TESTING MARKET, BY OFFERING 100 6.1 INTRODUCTION 101 6.2 PRODUCTS 101 6.2.1 CONSUMABLES 105 6.2.1.1 Increasing focus on development of biologics and biosimilars to propel segment growth 105 6.2.2 INSTRUMENTS & SOFTWARE 109 6.2.2.1 Continuous advancement in analytical technologies to fuel segment growth 109 6.3 SERVICES 112 6.3.1 STRINGENT REGULATORY STANDARDS TO PROMOTE MARKET GROWTH 112 7 RESIDUAL DNA TESTING MARKET, BY TEST TYPE 116 7.1 INTRODUCTION 117 7.2 FINAL PRODUCT RELEASE TESTING 117 7.2.1 FAVORABLE REGULATORY MANDATES AND BIOLOGICS INNOVATION TO FUEL MARKET GROWTH 117 7.3 BULK LOT RELEASE TESTING 121 7.3.1 INCREASING BIOLOGIC COMPLEXITY TO FUEL MARKET GROWTH 121 7.4 RAW MATERIAL TESTING 124 7.4.1 ENHANCED FOCUS ON PRODUCT SAFETY AND REGULATORY COMPLIANCE TO AUGMENT MARKET GROWTH 124 8 RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY 128 8.1 INTRODUCTION 129 8.2 POLYMERASE CHAIN REACTION 129 8.2.1 HIGH THROUGHPUT DETECTION TO SUPPORT SEGMENT DOMINANCE 129 8.3 THRESHOLD ASSAYS 133 8.3.1 HIGH SPECIFICITY OF DNA DETECTION AT LOW CONCENTRATION TO FUEL MARKET GROWTH 133 8.4 DNA PROBE HYBRIDIZATION 136 8.4.1 EASY-TO-USE PORTFOLIO TO BOOST ADOPTION OF DNA PROBE HYBRIDIZATION 136 8.5 OTHER TECHNOLOGIES 140 9 RESIDUAL DNA TESTING MARKET, BY APPLICATION 144 9.1 INTRODUCTION 145 9.2 MONOCLONAL ANTIBODIES 145 9.2.1 EXPANSION OF BIOSIMILAR PIPELINE TO AID MARKET GROWTH 145 9.3 CELL & GENE THERAPY 149 9.3.1 RISING POPULARITY OF VIRAL VECTOR-BASED SYSTEMS AND INCREASING REGULATORY APPROVALS TO AID MARKET GROWTH 149 9.4 VACCINES 152 9.4.1 PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 152 9.5 OTHER APPLICATIONS 156 10 RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER 159 10.1 INTRODUCTION 160 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 160 10.2.1 HIGH BIOPHARMACEUTICAL R&D SPENDING AND INCREASED REGULATORY PRESSURE TO FUEL MARKET GROWTH 160 10.3 CROS & CDMOS 164 10.3.1 FOCUS ON BIOLOGICS DEVELOPMENT AND CDMO FACILITY EXPANSION TO BOOST MARKET GROWTH 164 10.4 ACADEMIC & RESEARCH INSTITUTES 167 10.4.1 SURGE IN R&D ACTIVITIES FOR DEVELOPMENT OF ADVANCED THERAPIES TO DRIVE MARKET GROWTH 167 11 RESIDUAL DNA TESTING SERVICES MARKET, BY END USER 171 11.1 INTRODUCTION 172 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 172 11.2.1 SURGE IN R&D INVESTMENTS IN BIOPHARMACEUTICAL INNOVATION TO PROPEL MARKET GROWTH 172 11.3 ACADEMIC & RESEARCH INSTITUTES 176 11.3.1 SSLIMITED IN-HOUSE CAPABILITIES TO DRIVE OUTSOURCING 176 12 RESIDUAL DNA TESTING MARKET, BY REGION 180 12.1 INTRODUCTION 181 12.2 NORTH AMERICA 182 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 183 12.2.2 US 188 12.2.2.1 US to dominate North American residual DNA testing market during study period 188 12.2.3 CANADA 191 12.2.3.1 Increasing government support for biologics manufacturing and rising research funding to propel market growth 191 12.3 EUROPE 194 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 194 12.3.2 GERMANY 198 12.3.2.1 Increasing investments in biopharma and rising focus on developing manufacturing capabilities to drive market 198 12.3.3 UK 201 12.3.3.1 Booming life science industry and growing focus on vaccine development to aid market growth 201 12.3.4 FRANCE 204 12.3.4.1 Growing biotechnology sector and rising research funding to drive market 204 12.3.5 ITALY 207 12.3.5.1 High R&D investments in life sciences research to augment market growth 207 12.3.6 SPAIN 210 12.3.6.1 Increasing number of biotech companies to favor market growth 210 12.3.7 REST OF EUROPE 213 12.4 ASIA PACIFIC 215 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 216 12.4.2 CHINA 221 12.4.2.1 High R&D expenditure and favorable strategic alliances to propel market growth 221 12.4.3 JAPAN 224 12.4.3.1 Favorable government initiatives for drug development to support market growth 224 12.4.4 INDIA 227 12.4.4.1 Increasing R&D investments and funding for life science research to support market growth 227 12.4.5 SOUTH KOREA 230 12.4.5.1 Increasing strategic alliances and investments to spur market growth 230 12.4.6 AUSTRALIA 233 12.4.6.1 Booming life science sector to fuel market growth 233 12.4.7 REST OF ASIA PACIFIC 236 12.5 LATIN AMERICA 238 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 239 12.5.2 BRAZIL 242 12.5.2.1 Substantial R&D investments by pharmaceutical companies to fuel market growth 242 12.5.3 MEXICO 245 12.5.3.1 Rising government support for biopharmaceutical production to drive market 245 12.5.4 REST OF LATIN AMERICA 248 12.6 MIDDLE EAST 250 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 251 12.6.2 GCC COUNTRIES 254 12.6.2.1 Kingdom of Saudi Arabia 258 12.6.2.1.1 Increasing R&D investments in pharmaceutical industries to drive market 258 12.6.2.2 UAE 261 12.6.2.2.1 Investments in biopharma sector to offer growth opportunities 261 12.6.2.3 Rest of GCC Countries 263 12.6.3 REST OF MIDDLE EAST 266 12.7 AFRICA 269 12.7.1 RISING PREVALENCE OF CHRONIC DISEASES AND INCREASING FUNDING FOR BIOPHARMA SECTOR TO FUEL MARKET GROWTH 269 12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 269 13 COMPETITIVE LANDSCAPE 273 13.1 INTRODUCTION 273 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 273 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN RESIDUAL DNA TESTING MARKET 274 13.3 REVENUE ANALYSIS, 2020–2024 275 13.4 MARKET SHARE ANALYSIS, 2024 275 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 278 13.5.1 STARS 278 13.5.2 EMERGING LEADERS 278 13.5.3 PERVASIVE PLAYERS 278 13.5.4 PARTICIPANTS 278 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 280 13.5.5.1 Company footprint 280 13.5.5.2 Region footprint 281 13.5.5.3 Offering footprint 282 13.5.5.4 Technology footprint 283 13.5.5.5 Test type footprint 284 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 285 13.6.1 PROGRESSIVE COMPANIES 285 13.6.2 RESPONSIVE COMPANIES 285 13.6.3 DYNAMIC COMPANIES 285 13.6.4 STARTING BLOCKS 285 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 287 13.6.5.1 Detailed list of key startups/SMEs 287 13.6.5.2 Competitive benchmarking of Key startups/SMEs 288 13.7 COMPANY VALUATION & FINANCIAL METRICS 289 13.7.1 FINANCIAL METRICS 289 13.7.2 COMPANY VALUATION 289 13.8 BRAND/PRODUCT COMPARISON 290 13.9 COMPETITIVE SCENARIO 291 13.9.1 PRODUCT LAUNCHES 291 13.9.2 DEALS 292 13.9.3 OTHER DEVELOPMENTS 292   14 COMPANY PROFILES 293 14.1 KEY PLAYERS 293 14.1.1 THERMO FISHER SCIENTIFIC INC. 293 14.1.1.1 Business overview 293 14.1.1.2 Products/Services offered 295 14.1.1.3 Recent developments 296 14.1.1.3.1 Expansions 296 14.1.1.3.2 Other developments 296 14.1.1.4 MnM view 297 14.1.1.4.1 Key strengths 297 14.1.1.4.2 Strategic choices 297 14.1.1.4.3 Weaknesses & competitive threats 297 14.1.2 CHARLES RIVER LABORATORIES 298 14.1.2.1 Business overview 298 14.1.2.2 Products/Services offered 299 14.1.2.3 Recent developments 300 14.1.2.3.1 Expansions 300 14.1.2.4 MnM view 300 14.1.2.4.1 Key strengths 300 14.1.2.4.2 Strategic choices 300 14.1.2.4.3 Weaknesses & competitive threats 300 14.1.3 F. HOFFMANN-LA ROCHE LTD. 301 14.1.3.1 Business overview 301 14.1.3.2 Products/Services offered 302 14.1.3.3 Recent developments 303 14.1.3.3.1 Product launches 303 14.1.3.4 MnM view 303 14.1.3.4.1 Key strengths 303 14.1.3.4.2 Strategic choices 303 14.1.3.4.3 Weaknesses & competitive threats 303 14.1.4 MERCK KGAA 304 14.1.4.1 Business overview 304 14.1.4.2 Products/Services offered 305 14.1.4.3 Recent developments 306 14.1.4.3.1 Product launches 306 14.1.4.3.2 Expansions 306 14.1.4.4 MnM view 307 14.1.4.4.1 Key strengths 307 14.1.4.4.2 Strategic choices 307 14.1.4.4.3 Weaknesses & competitive threats 307   14.1.5 MARAVAI LIFESCIENCES 308 14.1.5.1 Business overview 308 14.1.5.2 Products/Services offered 310 14.1.5.3 Recent developments 311 14.1.5.3.1 Deals 311 14.1.5.4 MnM view 311 14.1.5.4.1 Key strengths 311 14.1.5.4.2 Strategic choices 311 14.1.5.4.3 Weaknesses & competitive threats 311 14.1.6 EUROFINS SCIENTIFIC 312 14.1.6.1 Business overview 312 14.1.6.2 Products/Services offered 314 14.1.6.3 Recent developments 314 14.1.6.3.1 Deals 314 14.1.7 BIO-RAD LABORATORIES, INC. 315 14.1.7.1 Business overview 315 14.1.7.2 Products/Services offered 317 14.1.7.3 Recent developments 318 14.1.7.3.1 Deals 318 14.1.8 QIAGEN 319 14.1.8.1 Business overview 319 14.1.8.2 Products/Services offered 321 14.1.8.3 Recent developments 321 14.1.8.3.1 Product launches 321 14.1.9 FUJIFILM CORPORATION 322 14.1.9.1 Business overview 322 14.1.9.2 Products/Services offered 324 14.1.10 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA. 325 14.1.10.1 Business overview 325 14.1.10.2 Products/Services offered 326 14.1.11 HILLGENE BIOPHARMA CO., LTD. 327 14.1.11.1 Business overview 327 14.1.11.2 Products/Services offered 329 14.1.12 REVVITY 330 14.1.12.1 Business overview 330 14.1.12.2 Products/Services offered 332 14.1.12.3 Recent developments 332 14.1.12.3.1 Product launches 332 14.1.13 INTERTEK GROUP PLC 333 14.1.13.1 Business overview 333 14.1.13.2 Products/Services offered 334   14.1.14 SARTORIUS AG 335 14.1.14.1 Business overview 335 14.1.14.2 Products/Services offered 336 14.1.15 LONZA 337 14.1.15.1 Business overview 337 14.1.15.2 Products/Services offered 338 14.1.16 WUXI APPTEC 339 14.1.16.1 Business overview 339 14.1.16.2 Products/Services offered 340 14.2 OTHER PLAYERS 341 14.2.1 TRANSGEN BIOTECH CO., LTD. 341 14.2.2 EAGLEBIO 342 14.2.3 YEASEN 343 14.2.4 ACROBIOSYSTEMS 344 14.2.5 CREATIVE BIOGENE 345 14.2.6 MINERVA BIOLABS GMBH 346 14.2.7 CREATIVE PROTEOMICS 347 14.2.8 AVANCE BIOSCIENCES 348 14.2.9 GENERI BIOTECH 349 15 APPENDIX 350 15.1 DISCUSSION GUIDE 350 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 353 15.3 CUSTOMIZATION OPTIONS 355 15.4 RELATED REPORTS 355 15.5 AUTHOR DETAILS 356
圖表清單 List of Tables & Figures
TABLE 1 RESIDUAL DNA TESTING MARKET: INCLUSIONS & EXCLUSIONS 38 TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 48 TABLE 3 RESIDUAL DNA TESTING MARKET: RISK ANALYSIS 51 TABLE 4 RESIDUAL DNA TESTING MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 61 TABLE 5 LIST OF FDA-APPROVED BIOSIMILAR PRODUCTS, 2022–2024 62 TABLE 6 KEY PRODUCT APPROVALS IN GENE THERAPY MARKET, 2022–2024 66 TABLE 7 AVERAGE SELLING PRICE TREND OF RESIDUAL DNA TESTING PRODUCTS, BY KEY PLAYER, 2022–2024 (USD MILLION) 70 TABLE 8 AVERAGE SELLING PRICE TREND OF RESIDUAL DNA QUANTIFICATION KITS, BY REGION, 2022–2024 (USD MILLION) 71 TABLE 9 AVERAGE SELLING PRICE TREND OF PCR INSTRUMENTS, BY REGION, 2022–2024 (USD MILLION) 72 TABLE 10 RESIDUAL DNA TESTING MARKET: ROLE IN ECOSYSTEM 76 TABLE 11 MAJOR INVESTMENT AND FUNDING ACTIVITIES IN RESIDUAL DNA TESTING MARKET, BY KEY PLAYER, 2022−2025 77 TABLE 12 RESIDUAL DNA TESTING MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2024 82 TABLE 13 RESIDUAL DNA TESTING MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 83 TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86 TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86 TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87 TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87 TABLE 18 RESIDUAL DNA TESTING MARKET: PORTER’S FIVE FORCES 88 TABLE 19 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING (%) 90 TABLE 20 KEY BUYING CRITERIA, BY END USER 91 TABLE 21 LIST OF KEY COMPANIES IMPLEMENTING AI/GEN AI IN RESIDUAL DNA TESTING MARKET 93 TABLE 22 RESIDUAL DNA TESTING MARKET: IMPORT DATA FOR HS CODE 9027, 2020–2024 (USD THOUSAND) 94 TABLE 23 RESIDUAL DNA TESTING MARKET: EXPORT DATA FOR HS CODE 9027, 2020–2024 (USD THOUSAND) 95 TABLE 24 US ADJUSTED RECIPROCAL TARIFF RATES 96 TABLE 25 PRODUCT/COMPONENT-RELATED TARIFFS FOR RESIDUAL DNA TESTING PRODUCTS 97 TABLE 26 CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES 97 TABLE 27 RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 101 TABLE 28 RESIDUAL DNA TESTING PRODUCTS MARKET, BY REGION, 2023–2030 (USD MILLION) 102 TABLE 29 NORTH AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 102 TABLE 30 EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 31 ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 32 LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 33 MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET, BY REGION, 2023–2030 (USD MILLION) 104 TABLE 34 GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 35 RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 105 TABLE 36 RESIDUAL DNA TESTING CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION) 106 TABLE 37 NORTH AMERICA: RESIDUAL DNA TESTING CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 38 EUROPE: RESIDUAL DNA TESTING CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 39 ASIA PACIFIC: RESIDUAL DNA TESTING CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 40 LATIN AMERICA: RESIDUAL DNA TESTING CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 41 MIDDLE EAST: RESIDUAL DNA TESTING CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 42 GCC COUNTRIES: RESIDUAL DNA TESTING CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 43 RESIDUAL DNA TESTING INSTRUMENTS & SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION) 109 TABLE 44 NORTH AMERICA: RESIDUAL DNA TESTING INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 45 EUROPE: RESIDUAL DNA TESTING INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 46 ASIA PACIFIC: RESIDUAL DNA TESTING INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 47 LATIN AMERICA: RESIDUAL DNA TESTING INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 48 MIDDLE EAST: RESIDUAL DNA TESTING INSTRUMENTS & SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION) 111 TABLE 49 GCC COUNTRIES: RESIDUAL DNA TESTING INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 50 RESIDUAL DNA TESTING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 113 TABLE 51 NORTH AMERICA: RESIDUAL DNA TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 52 EUROPE: RESIDUAL DNA TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 53 ASIA PACIFIC: RESIDUAL DNA TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 54 LATIN AMERICA: RESIDUAL DNA TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 55 MIDDLE EAST: RESIDUAL DNA TESTING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 115 TABLE 56 GCC COUNTRIES: RESIDUAL DNA TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 57 RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 117 TABLE 58 RESIDUAL DNA FINAL PRODUCT RELEASE TESTING MARKET, BY REGION, 2023–2030 (USD MILLION) 118 TABLE 59 NORTH AMERICA: RESIDUAL DNA FINAL PRODUCT RELEASE TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 60 EUROPE: RESIDUAL DNA FINAL PRODUCT RELEASE TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 61 ASIA PACIFIC: RESIDUAL DNA FINAL PRODUCT RELEASE TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 62 LATIN AMERICA: RESIDUAL DNA FINAL PRODUCT RELEASE TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 63 MIDDLE EAST: RESIDUAL DNA FINAL PRODUCT RELEASE TESTING MARKET, BY REGION, 2023–2030 (USD MILLION) 120 TABLE 64 GCC COUNTRIES: RESIDUAL DNA FINAL PRODUCT RELEASE TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 65 RESIDUAL DNA BULK LOT RELEASE TESTING MARKET, BY REGION, 2023–2030 (USD MILLION) 121 TABLE 66 NORTH AMERICA: RESIDUAL DNA BULK LOT RELEASE TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 67 EUROPE: RESIDUAL DNA BULK LOT RELEASE TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 68 ASIA PACIFIC: RESIDUAL DNA BULK LOT RELEASE TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 69 LATIN AMERICA: RESIDUAL DNA BULK LOT RELEASE TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 70 MIDDLE EAST: RESIDUAL DNA BULK LOT RELEASE TESTING MARKET, BY REGION, 2023–2030 (USD MILLION) 123 TABLE 71 GCC COUNTRIES: RESIDUAL DNA BULK LOT RELEASE TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 72 RESIDUAL DNA RAW MATERIAL TESTING MARKET, BY REGION, 2023–2030 (USD MILLION) 125 TABLE 73 NORTH AMERICA: RESIDUAL DNA RAW MATERIAL TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 74 EUROPE: RESIDUAL DNA RAW MATERIAL TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 75 ASIA PACIFIC: RESIDUAL DNA RAW MATERIAL TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 76 LATIN AMERICA: RESIDUAL DNA RAW MATERIAL TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 77 MIDDLE EAST: RESIDUAL DNA RAW MATERIAL TESTING MARKET, BY REGION, 2023–2030 (USD MILLION) 127 TABLE 78 GCC COUNTRIES: RESIDUAL DNA RAW MATERIAL TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 79 RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 129 TABLE 80 RESIDUAL DNA TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION) 130 TABLE 81 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 82 EUROPE: RESIDUAL DNA TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 83 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 84 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 85 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION) 132 TABLE 86 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 87 RESIDUAL DNA TESTING MARKET FOR THRESHOLD ASSAYS, BY REGION, 2023–2030 (USD MILLION) 133 TABLE 88 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR THRESHOLD ASSAYS, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 89 EUROPE: RESIDUAL DNA TESTING MARKET FOR THRESHOLD ASSAYS, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 90 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR THRESHOLD ASSAYS, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 91 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR THRESHOLD ASSAYS, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 92 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR THRESHOLD ASSAYS, BY REGION, 2023–2030 (USD MILLION) 135 TABLE 93 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR THRESHOLD ASSAYS, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 94 RESIDUAL DNA TESTING MARKET FOR DNA PROBE HYBRIDIZATION, BY REGION, 2023–2030 (USD MILLION) 137 TABLE 95 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR DNA PROBE HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 96 EUROPE: RESIDUAL DNA TESTING MARKET FOR DNA PROBE HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 97 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR DNA PROBE HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 98 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR DNA PROBE HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 99 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR DNA PROBE HYBRIDIZATION, BY REGION, 2023–2030 (USD MILLION) 139 TABLE 100 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR DNA PROBE HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 101 RESIDUAL DNA TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION) 140 TABLE 102 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 103 EUROPE: RESIDUAL DNA TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 104 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 105 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 106 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION) 143 TABLE 107 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 108 RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 145 TABLE 109 RESIDUAL DNA TESTING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION) 146 TABLE 110 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 111 EUROPE: RESIDUAL DNA TESTING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 112 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 113 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 114 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION) 148 TABLE 115 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 116 RESIDUAL DNA TESTING MARKET FOR CELL & GENE THERAPY, BY REGION, 2023–2030 (USD MILLION) 149 TABLE 117 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 118 EUROPE: RESIDUAL DNA TESTING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 119 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 120 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 121 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR CELL & GENE THERAPY, BY REGION, 2023–2030 (USD MILLION) 151 TABLE 122 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 123 RESIDUAL DNA TESTING MARKET FOR VACCINES, BY REGION, 2023–2030 (USD MILLION) 153 TABLE 124 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 125 EUROPE: RESIDUAL DNA TESTING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 126 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 127 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 128 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR VACCINES, BY REGION, 2023–2030 (USD MILLION) 155 TABLE 129 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 130 RESIDUAL DNA TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 156 TABLE 131 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 132 EUROPE: RESIDUAL DNA TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 133 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 134 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 135 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 158 TABLE 136 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 137 RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 160 TABLE 138 RESIDUAL DNA TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 161 TABLE 139 NORTH AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 140 EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 141 ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 142 LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 143 MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 163 TABLE 144 GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 145 RESIDUAL DNA TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2023–2030 (USD MILLION) 164 TABLE 146 NORTH AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 147 EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 148 ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 149 LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 150 MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2023–2030 (USD MILLION) 166 TABLE 151 GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 152 RESIDUAL DNA TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 167 TABLE 153 NORTH AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 154 EUROPE: RESIDUAL DNA TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 155 ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 156 LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 157 MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 170 TABLE 158 GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 159 RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 172 TABLE 160 RESIDUAL DNA TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 173 TABLE 161 NORTH AMERICA: RESIDUAL DNA TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 162 EUROPE: RESIDUAL DNA TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 163 ASIA PACIFIC: RESIDUAL DNA TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 164 LATIN AMERICA: RESIDUAL DNA TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 165 MIDDLE EAST: RESIDUAL DNA TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 175 TABLE 166 GCC COUNTRIES: RESIDUAL DNA TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 167 RESIDUAL DNA TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 176 TABLE 168 NORTH AMERICA: RESIDUAL DNA TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 169 EUROPE: RESIDUAL DNA TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 170 ASIA PACIFIC: RESIDUAL DNA TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 171 LATIN AMERICA: RESIDUAL DNA TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 172 MIDDLE EAST: RESIDUAL DNA TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 178 TABLE 173 GCC COUNTRIES: RESIDUAL DNA TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 174 RESIDUAL DNA TESTING MARKET, BY REGION, 2023–2030 (USD MILLION) 181 TABLE 175 RESIDUAL DNA TESTING PRODUCTS MARKET, BY REGION, 2023–2030 (USD MILLION) 181 TABLE 176 RESIDUAL DNA TESTING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 182 TABLE 177 NORTH AMERICA: RESIDUAL DNA TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 184 TABLE 178 NORTH AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 179 NORTH AMERICA: RESIDUAL DNA TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 180 NORTH AMERICA: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 185 TABLE 181 NORTH AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 186 TABLE 182 NORTH AMERICA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 186 TABLE 183 NORTH AMERICA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 186 TABLE 184 NORTH AMERICA: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 187 TABLE 185 NORTH AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 187 TABLE 186 NORTH AMERICA: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 187 TABLE 187 US: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 189 TABLE 188 US: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 189 TABLE 189 US: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 189 TABLE 190 US: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 190 TABLE 191 US: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 190 TABLE 192 US: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 190 TABLE 193 US: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 191 TABLE 194 CANADA: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 191 TABLE 195 CANADA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 192 TABLE 196 CANADA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 192 TABLE 197 CANADA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 192 TABLE 198 CANADA: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 193 TABLE 199 CANADA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 193 TABLE 200 CANADA: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 193 TABLE 201 EUROPE: RESIDUAL DNA TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 195 TABLE 202 EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 195 TABLE 203 EUROPE: RESIDUAL DNA TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 204 EUROPE: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 196 TABLE 205 EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 196 TABLE 206 EUROPE: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 197 TABLE 207 EUROPE: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 197 TABLE 208 EUROPE: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 197 TABLE 209 EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 198 TABLE 210 EUROPE: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 198 TABLE 211 GERMANY: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 199 TABLE 212 GERMANY: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 199 TABLE 213 GERMANY: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 199 TABLE 214 GERMANY: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 200 TABLE 215 GERMANY: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 200 TABLE 216 GERMANY: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 200 TABLE 217 GERMANY: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 201 TABLE 218 UK: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 202 TABLE 219 UK: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 202 TABLE 220 UK: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 202 TABLE 221 UK: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 203 TABLE 222 UK: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 203 TABLE 223 UK: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 203 TABLE 224 UK: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 204 TABLE 225 FRANCE: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 205 TABLE 226 FRANCE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 205 TABLE 227 FRANCE: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 205 TABLE 228 FRANCE: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 206 TABLE 229 FRANCE: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 206 TABLE 230 FRANCE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 206 TABLE 231 FRANCE: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 207 TABLE 232 ITALY: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 207 TABLE 233 ITALY: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 208 TABLE 234 ITALY: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 208 TABLE 235 ITALY: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 208 TABLE 236 ITALY: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 209 TABLE 237 ITALY: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 209 TABLE 238 ITALY: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 209 TABLE 239 SPAIN: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 210 TABLE 240 SPAIN: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 211 TABLE 241 SPAIN: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 211 TABLE 242 SPAIN: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 211 TABLE 243 SPAIN: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 212 TABLE 244 SPAIN: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 212 TABLE 245 SPAIN: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 212 TABLE 246 REST OF EUROPE: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 213 TABLE 247 REST OF EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 213 TABLE 248 REST OF EUROPE: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 214 TABLE 249 REST OF EUROPE: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 214 TABLE 250 REST OF EUROPE: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 214 TABLE 251 REST OF EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER,2023–2030 (USD MILLION) 215 TABLE 252 REST OF EUROPE: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 215 TABLE 253 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 218 TABLE 254 ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 218 TABLE 255 ASIA PACIFIC: RESIDUAL DNA TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 219 TABLE 256 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 219 TABLE 257 ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 219 TABLE 258 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 220 TABLE 259 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 220 TABLE 260 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 220 TABLE 261 ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 221 TABLE 262 ASIA PACIFIC: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 221 TABLE 263 CHINA: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 222 TABLE 264 CHINA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 222 TABLE 265 CHINA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 223 TABLE 266 CHINA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 223 TABLE 267 CHINA: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 223 TABLE 268 CHINA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 224 TABLE 269 CHINA: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 224 TABLE 270 JAPAN: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 225 TABLE 271 JAPAN: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 225 TABLE 272 JAPAN: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 226 TABLE 273 JAPAN: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 226 TABLE 274 JAPAN: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 226 TABLE 275 JAPAN: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 227 TABLE 276 JAPAN: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 227 TABLE 277 INDIA: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 228 TABLE 278 INDIA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 228 TABLE 279 INDIA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 229 TABLE 280 INDIA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 229 TABLE 281 INDIA: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 229 TABLE 282 INDIA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 230 TABLE 283 INDIA: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 230 TABLE 284 SOUTH KOREA: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 231 TABLE 285 SOUTH KOREA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 231 TABLE 286 SOUTH KOREA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 231 TABLE 287 SOUTH KOREA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 232 TABLE 288 SOUTH KOREA: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 232 TABLE 289 SOUTH KOREA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 232 TABLE 290 SOUTH KOREA: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 233 TABLE 291 AUSTRALIA: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 233 TABLE 292 AUSTRALIA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 234 TABLE 293 AUSTRALIA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 234 TABLE 294 AUSTRALIA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 234 TABLE 295 AUSTRALIA: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 235 TABLE 296 AUSTRALIA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 235 TABLE 297 AUSTRALIA: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 235 TABLE 298 REST OF ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 236 TABLE 299 REST OF ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 236 TABLE 300 REST OF ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 237 TABLE 301 REST OF ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 237 TABLE 302 REST OF ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 237 TABLE 303 REST OF ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 238 TABLE 304 REST OF ASIA PACIFIC: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 238 TABLE 305 LATIN AMERICA: RESIDUAL DNA TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 239 TABLE 306 LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 239 TABLE 307 LATIN AMERICA: RESIDUAL DNA TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 240 TABLE 308 LATIN AMERICA: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 240 TABLE 309 LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 240 TABLE 310 LATIN AMERICA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 241 TABLE 311 LATIN AMERICA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 241 TABLE 312 LATIN AMERICA: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 241 TABLE 313 LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 242 TABLE 314 LATIN AMERICA: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 242 TABLE 315 BRAZIL: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 243 TABLE 316 BRAZIL: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 243 TABLE 317 BRAZIL: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 243 TABLE 318 BRAZIL: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 244 TABLE 319 BRAZIL: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 244 TABLE 320 BRAZIL: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 244 TABLE 321 BRAZIL: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 245 TABLE 322 MEXICO: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 245 TABLE 323 MEXICO: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 246 TABLE 324 MEXICO: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 246 TABLE 325 MEXICO: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 246 TABLE 326 MEXICO: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 247 TABLE 327 MEXICO: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 247 TABLE 328 MEXICO: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 247 TABLE 329 REST OF LATIN AMERICA: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 248 TABLE 330 REST OF LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 248 TABLE 331 REST OF LATIN AMERICA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 249 TABLE 332 REST OF LATIN AMERICA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 249 TABLE 333 REST OF LATIN AMERICA: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 249 TABLE 334 REST OF LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 250 TABLE 335 REST OF LATIN AMERICA: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 250 TABLE 336 MIDDLE EAST: RESIDUAL DNA TESTING MARKET, BY REGION, 2023–2030 (USD MILLION) 251 TABLE 337 MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET, BY REGION, 2023–2030 (USD MILLION) 251 TABLE 338 MIDDLE EAST: RESIDUAL DNA TESTING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 252 TABLE 339 MIDDLE EAST: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 252 TABLE 340 MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 252 TABLE 341 MIDDLE EAST: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 253 TABLE 342 MIDDLE EAST: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 253 TABLE 343 MIDDLE EAST: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 253 TABLE 344 MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 254 TABLE 345 MIDDLE EAST: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 254 TABLE 346 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 255 TABLE 347 GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 255 TABLE 348 GCC COUNTRIES: RESIDUAL DNA TESTING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 255 TABLE 349 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 256 TABLE 350 GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 256 TABLE 351 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 256 TABLE 352 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 257 TABLE 353 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 257 TABLE 354 GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 257 TABLE 355 GCC COUNTRIES: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 258 TABLE 356 KINGDOM OF SAUDI ARABIA: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 258 TABLE 357 KINGDOM OF SAUDI ARABIA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 259 TABLE 358 KINGDOM OF SAUDI ARABIA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 259 TABLE 359 KINGDOM OF SAUDI ARABIA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 259 TABLE 360 KINGDOM OF SAUDI ARABIA: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 260 TABLE 361 KINGDOM OF SAUDI ARABIA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 260 TABLE 362 KINGDOM OF SAUDI ARABIA: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 260 TABLE 363 UAE: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 261 TABLE 364 UAE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 261 TABLE 365 UAE: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 262 TABLE 366 UAE: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 262 TABLE 367 UAE: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 262 TABLE 368 UAE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 263 TABLE 369 UAE: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 263 TABLE 370 REST OF GCC COUNTRIES: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 264 TABLE 371 REST OF GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 264 TABLE 372 REST OF GCC COUNTRIES: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 264 TABLE 373 REST OF GCC COUNTRIES: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 265 TABLE 374 REST OF GCC COUNTRIES: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 265 TABLE 375 REST OF GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 265 TABLE 376 REST OF GCC COUNTRIES: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 266 TABLE 377 REST OF MIDDLE EAST: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 266 TABLE 378 REST OF MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 267 TABLE 379 REST OF MIDDLE EAST: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 267 TABLE 380 REST OF MIDDLE EAST: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 267 TABLE 381 REST OF MIDDLE EAST: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 268 TABLE 382 REST OF MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 268 TABLE 383 REST OF MIDDLE EAST: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 268 TABLE 384 AFRICA: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 270 TABLE 385 AFRICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 270 TABLE 386 AFRICA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 270 TABLE 387 AFRICA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 271 TABLE 388 AFRICA: RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 271 TABLE 389 AFRICA: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 271 TABLE 390 AFRICA: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 272 TABLE 391 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN RESIDUAL DNA TESTING MARKET 274 TABLE 392 RESIDUAL DNA TESTING MARKET: DEGREE OF COMPETITION 276 TABLE 393 RESIDUAL DNA TESTING MARKET: REGION FOOTPRINT 281 TABLE 394 RESIDUAL DNA TESTING MARKET: OFFERING FOOTPRINT 282 TABLE 395 RESIDUAL DNA TESTING MARKET: TECHNOLOGY FOOTPRINT 283 TABLE 396 RESIDUAL DNA TESTING MARKET: TEST TYPE FOOTPRINT 284 TABLE 397 RESIDUAL DNA TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES 287 TABLE 398 RESIDUAL DNA TESTING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS 288 TABLE 399 RESIDUAL DNA TESTING MARKET: PRODUCT LAUNCHES, JANUARY 2021–MAY 2025 291 TABLE 400 RESIDUAL DNA TESTING MARKET: DEALS, JANUARY 2021–MAY 2025 292 TABLE 401 RESIDUAL DNA TESTING MARKET: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2025 292 TABLE 402 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 293 TABLE 403 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 295 TABLE 404 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–MAY 2025 296 TABLE 405 THERMO FISHER SCIENTIFIC INC.: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025 296 TABLE 406 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW 298 TABLE 407 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED 299 TABLE 408 CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2022–MAY 2025 300 TABLE 409 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 301 TABLE 410 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED 302 TABLE 411 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 303 TABLE 412 MERCK KGAA: COMPANY OVERVIEW 304 TABLE 413 MERCK KGAA: PRODUCTS/SERVICES OFFERED 305 TABLE 414 MERCK KGAA: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 306 TABLE 415 MERCK KGAA: EXPANSIONS, JANUARY 2022–MAY 2025 306 TABLE 416 MARAVAI LIFESCIENCES: COMPANY OVERVIEW 308 TABLE 417 MARAVAI LIFESCIENCES: PRODUCTS/SERVICES OFFERED 310 TABLE 418 MARAVAI LIFESCIENCES: DEALS, JANUARY 2022–MAY 2025 311 TABLE 419 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 312 TABLE 420 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES OFFERED 314 TABLE 421 EUROFINS SCIENTIFIC: DEALS, JANUARY 2022–MAY 2025 314 TABLE 422 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 315 TABLE 423 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED 317 TABLE 424 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022–MAY 2025 318 TABLE 425 QIAGEN: COMPANY OVERVIEW 319 TABLE 426 QIAGEN: PRODUCTS/SERVICES OFFERED 321 TABLE 427 QIAGEN: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 321 TABLE 428 FUJIFILM CORPORATION: COMPANY OVERVIEW 322 TABLE 429 FUJIFILM CORPORATION: PRODUCTS/SERVICES OFFERED 324 TABLE 430 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA.: COMPANY OVERVIEW 325 TABLE 431 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA.: PRODUCTS/SERVICES OFFERED 326 TABLE 432 HILLGENE BIOPHARMA CO., LTD.: COMPANY OVERVIEW 327 TABLE 433 HILLGENE BIOPHARMA CO., LTD.: PRODUCTS/SERVICES OFFERED 329 TABLE 434 REVVITY: COMPANY OVERVIEW 330 TABLE 435 REVVITY: PRODUCTS/SERVICES OFFERED 332 TABLE 436 REVVITY: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 332 TABLE 437 INTERTEK GROUP PLC: COMPANY OVERVIEW 333 TABLE 438 INTERTEK GROUP PLC: PRODUCTS/SERVICES OFFERED 334 TABLE 439 SARTORIUS AG: COMPANY OVERVIEW 335 TABLE 440 SARTORIUS AG: PRODUCTS/SERVICES OFFERED 336 TABLE 441 LONZA: COMPANY OVERVIEW 337 TABLE 442 LONZA: PRODUCTS/SERVICES OFFERED 338 TABLE 443 WUXI APPTEC: COMPANY OVERVIEW 339 TABLE 444 WUXI APPTEC: PRODUCTS/SERVICES OFFERED 340 TABLE 445 TRANSGEN BIOTECH CO., LTD.: COMPANY OVERVIEW 341 TABLE 446 EAGLEBIO: COMPANY OVERVIEW 342 TABLE 447 YEASEN: COMPANY OVERVIEW 343 TABLE 448 ACROBIOSYSTEMS: COMPANY OVERVIEW 344 TABLE 449 CREATIVE BIOGENE: COMPANY OVERVIEW 345 TABLE 450 MINERVA BIOLABS GMBH: COMPANY OVERVIEW 346 TABLE 451 CREATIVE PROTEOMICS: COMPANY OVERVIEW 347 TABLE 452 AVANCE BIOSCIENCES: COMPANY OVERVIEW 348 TABLE 453 GENERI BIOTECH: COMPANY OVERVIEW 349 FIGURE 1 RESIDUAL DNA TESTING MARKET SEGMENTATION & REGIONAL SCOPE 37 FIGURE 2 RESIDUAL DNA TESTING MARKET: YEARS CONSIDERED 39 FIGURE 3 RESIDUAL DNA TESTING MARKET: RESEARCH DESIGN 40 FIGURE 4 RESIDUAL DNA TESTING MARKET: BREAKDOWN OF PRIMARIES (SUPPLY- AND DEMAND-SIDE PARTICIPANTS) 42 FIGURE 5 RESIDUAL DNA TESTING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 43 FIGURE 6 RESIDUAL DNA TESTING MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2024) 44 FIGURE 7 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2024) 44 FIGURE 8 RESIDUAL DNA TESTING MARKET: INSIGHTS FROM PRIMARIES 45 FIGURE 9 RESIDUAL DNA TESTING MARKET: TOP-DOWN APPROACH 46 FIGURE 10 RESIDUAL DNA TESTING MARKET: CAGR PROJECTIONS 48 FIGURE 11 RESIDUAL DNA TESTING MARKET: DATA TRIANGULATION 49 FIGURE 12 RESIDUAL DNA TESTING MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION) 52 FIGURE 13 RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2025 VS. 2030 (USD MILLION) 53 FIGURE 14 RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION) 53 FIGURE 15 RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 54 FIGURE 16 RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 55 FIGURE 17 RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 55 FIGURE 18 REGIONAL ANALYSIS OF RESIDUAL DNA TESTING MARKET 56 FIGURE 19 INCREASE IN NUMBER OF BIOLOGICS AND BIOSIMILAR APPROVALS TO DRIVE MARKET 57 FIGURE 20 US AND FINAL PRODUCT RELEASE TESTING ACCOUNTED FOR LARGEST NORTH AMERICAN MARKET SHARE IN 2024 58 FIGURE 21 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES COMMANDED LARGEST MARKET SHARE IN 2024 58 FIGURE 22 CHINA TO WITNESS HIGHEST CAGR DURING STUDY PERIOD 59 FIGURE 23 RESIDUAL DNA TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60 FIGURE 24 GLOBAL TOTAL PHARMACEUTICAL R&D SPEND, 2016–2030 64 FIGURE 25 RESIDUAL DNA TESTING MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 69 FIGURE 26 AVERAGE SELLING PRICE OF DNA QUANTIFICATION KITS, BY KEY PLAYER, 2024 (USD) 70 FIGURE 27 AVERAGE SELLING PRICE TREND OF PCR SYSTEMS, BY KEY PLAYER, 2022–2024 (USD) 71 FIGURE 28 AVERAGE SELLING PRICE OF RESIDUAL DNA TESTING PRODUCTS, BY REGION, 2024 (USD) 72   FIGURE 29 RESIDUAL DNA TESTING MARKET: VALUE CHAIN ANALYSIS 73 FIGURE 30 RESIDUAL DNA TESTING MARKET: ECOSYSTEM ANALYSIS 76 FIGURE 31 FUNDING AND NUMBER OF DEALS IN RESIDUAL DNA TESTING MARKET, 2021–2024 78 FIGURE 32 TOP APPLICANTS OF RESIDUAL DNA TESTING PATENTS, 2014–2024 81 FIGURE 33 RESIDUAL DNA TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 88 FIGURE 34 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING 90 FIGURE 35 KEY BUYING CRITERIA, BY END USER 91 FIGURE 36 RESIDUAL DNA TESTING MARKET: KEY AI USE CASES 93 FIGURE 37 NORTH AMERICA: RESIDUAL DNA TESTING MARKET SNAPSHOT 184 FIGURE 38 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET SNAPSHOT 217 FIGURE 39 REVENUE ANALYSIS OF KEY PLAYERS IN RESIDUAL DNA TESTING MARKET, 2020–2024 (USD MILLION) 275 FIGURE 40 MARKET SHARE ANALYSIS OF KEY PLAYERS IN RESIDUAL DNA TESTING MARKET (2024) 276 FIGURE 41 RESIDUAL DNA TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 279 FIGURE 42 RESIDUAL DNA TESTING MARKET: COMPANY FOOTPRINT 280 FIGURE 43 RESIDUAL DNA TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 286 FIGURE 44 WEV/EBITDA OF KEY VENDORS 289 FIGURE 45 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 289 FIGURE 46 RESIDUAL DNA TESTING MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 290 FIGURE 47 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 294 FIGURE 48 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT 299 FIGURE 49 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT 302 FIGURE 50 MERCK KGAA: COMPANY SNAPSHOT 305 FIGURE 51 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT 309 FIGURE 52 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT 313 FIGURE 53 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 316 FIGURE 54 QIAGEN: COMPANY SNAPSHOT 320 FIGURE 55 FUJIFILM CORPORATION: COMPANY SNAPSHOT 323 FIGURE 56 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA.: COMPANY SNAPSHOT 326 FIGURE 57 HILLGENE BIOPHARMA CO., LTD.: COMPANY SNAPSHOT 328 FIGURE 58 REVVITY: COMPANY SNAPSHOT 331 FIGURE 59 INTERTEK GROUP PLC: COMPANY SNAPSHOT 334 FIGURE 60 SARTORIUS AG: COMPANY SNAPSHOT 336 FIGURE 61 LONZA: COMPANY SNAPSHOT 338 FIGURE 62 WUXI APPTEC: COMPANY SNAPSHOT 340

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們